EGFR Testing for Advanced Non-Small Cell Lung Cancer (NSCLC)

By: | Tags: | Comments: 0 | August 13th, 2016

  • NSCLC accounts for about 85% of lung cancers and includes predominantly adenocarcinomas and squamous cell carcinomas.
  • In the United States, about 15% of patients with NSCLC have mutations in Epidermal Growth Factor Recepter (EGFR).
  • Testing for EGFR mutations is performed to identify patients who may benefit from targeted therapy such as tyrosine kinase inhibitor (TKIs).Identification of EGFR mutations is now accepted as standard practice, supported by NCCN Clinical practice guidelines.
  • The presence of EGFR mutations may confer an improved response to anti EGFR-targeted therapy and can prove to be beneficial to such patients.

Result reported: Positive or Negative for EGFR mutations

Lincoln Labs EGFR Mutation Analysis offers:

  • Turnaround time of 7-10 days
  • Our highly qualified staff is accessible for any assistance regarding the tests.
  • Broad coverage by most private and public insurances.

Specimen Requirement:

  1. Formalin-fixed, paraffin-embedded (FFPE) tissues from routinely prepared small biopsies are practical and standard for EGFR mutation analysis.
  2. Specimens are optimally fixed in 10% neutral-buffered formalin, optimal fixation time ranges from 6 to 24 hours.
  3. Presence of tumor cells in the sample must be assessed by a pathologist.
  4. Ratio of tumor cells to normal cells is crucial for adequate mutation testing and should be provided by the pathologist.
  5. One H&E slide and 3-5 unstained slides (6-8microns ideal) are required for mutation testing.

Test Code:

ICD 10 Code:81235- EGFR (epidermal growth factor receptor) (eg, non-small cell lung cancer) gene analysis, common variants.

Leave a Reply

19 − three =